Most Recent
Delivering his findings on ASIC’s action against Star Entertainment executives on Thursday, Federal Court Justice Michael Lee remarked that the “self-congratulatory submissions" of former board members named in the case were "jarring”.
ASIC has had mixed success in a case against former Star directors and officers, with a judge finding the casino operator’s former CEO and GC breached their duties but that claims against the former board fell short.
McDonald’s has lost its bid to send a notice to group members foreshadowing its intention to apply for soft class closure in a representative case on behalf of 350,000 workers who were allegedly denied rest breaks.
Construction PRO
Dexus has halved the number of documents it claims are shielded by legal privilege from production to fellow owners of airport operator APAC ahead of trial over an alleged breach of a shareholder deed, a court heard Monday.
Special purpose liquidators have been appointed to failed clothing retailer Mosaic Brands, after a judge found a reasonable apprehension of bias arising from liquidator Vaughan Strawbridge's former link to Deloitte.
Construction PRO
A judge has struck out builder CPB Contractor's “clearly untenable” claim against Transport for NSW for $63 million in delay costs for work on the Pacific Highway upgrade.
Construction PRO
Transport for NSW has accused a former contractor of multiplying claims for delayed or disrupted work days by six or seven times in a $63 million dispute.
A judge overseeing a class action on behalf of 300,000 allegedly underpaid McDonald’s workers wants to know the monetary value of the claims, while also questioning why the initial trial in the complex case is set to run for 35 days.
Mayne Pharma and US drug maker Cosette have agreed to postpone the start of trial in a case over the termination of a $672 million merger to allow for late amendments.
Mayne Pharma has denied US drug maker Cosette's claims it breached its continuous disclosure obligations in relation to US FDA concerns about marketing for its Nextstellis contraceptive, as the drug makers spar over their $672 million merger.